Bristol Myers Squibb (CELG-RI) Net Cash Flow Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) Net Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 93.66% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -323.06% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 248.11% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 195.58% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -0.70% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 349.49% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -55.11% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -517.34% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 78.10% |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -152.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -152.92% |
| Mar 31, 2026 | -227.06% |
| Dec 31, 2025 | -311.96% |
| Sep 30, 2025 | 105.20% |
| Jun 30, 2025 | 153.32% |
| Mar 31, 2025 | 121.59% |
| Dec 31, 2024 | -32.84% |
| Sep 30, 2024 | 285.59% |
| Jun 30, 2024 | -390.41% |
| Mar 31, 2024 | -637.93% |
| Dec 31, 2023 | 204.24% |
| Sep 30, 2023 | 72.11% |
| Jun 30, 2023 | 60.27% |
| Mar 31, 2023 | 83.39% |
| Dec 31, 2022 | 159.27% |
| Sep 30, 2022 | -217.01% |
| Jun 30, 2022 | -2,768.97% |
| Mar 31, 2022 | 51.69% |
| Dec 31, 2021 | 109.87% |
| Sep 30, 2021 | 570.92% |